Biopharma
Connexius ADC Development & Manufacturing Asia 2028
- Date
- 24–25 May 2028
- Location
- Seoul, South Korea
Event information
- Date
- 24–25 May 2028
- Location
- Seoul, South Korea
Overview
Antibody-drug conjugates (ADCs) are becoming one of the most dynamic areas of oncology drug development, combining the targeting precision of monoclonal antibodies with highly potent therapeutic payloads. Across Asia, growing investment in ADC discovery, novel linker-payload technologies, bioconjugation and specialised manufacturing is creating new opportunities to develop differentiated therapies while addressing increasingly complex challenges around CMC, analytics, scale-up and commercial manufacturing.
Asia is already playing an increasingly important role in the global ADC ecosystem. South Korea has developed a strong combination of ADC innovation and manufacturing capability, with companies such as LigaChem Biosciences advancing proprietary ADC technologies and Samsung Biologics establishing dedicated ADC manufacturing capabilities in Songdo. In China, companies including RemeGen, DualityBio and Kelun-Biotech have built growing ADC pipelines and international partnerships, while Japan's Daiichi Sankyo has demonstrated the global potential of Asian ADC innovation through its DXd ADC technology and portfolio.
Taking place in Seoul, South Korea, Connexius ADC Development & Manufacturing Asia 2028 will bring together ADC developers, biopharma and biotech companies, CDMOs, research organisations and technology providers from South Korea, Japan, China, Singapore, India and across the wider Asia-Pacific region. The conference will connect expertise across ADC discovery and design, antibody engineering, linker and payload development, conjugation, analytical development, CMC, process development, HPAPI containment, scale-up and manufacturing.
From designing the next generation of ADCs to overcoming the challenges of producing them at commercial scale, the conference will provide a focused platform for the Asian ADC community to exchange technical expertise, discover enabling technologies and build new industry partnerships — supporting the continued growth of Asia as a major hub for ADC development and manufacturing.
Programme
Day 1 — Wednesday 24 May 2028
- 08:30
Registration & Welcome Coffee
- 09:00
Chairperson's Welcome & Opening Remarks
- 09:10
SESSION I - ASIA ADC DEVELOPMENT & INNOVATION OUTLOOK
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION II: ANTIBODY ENGINEERING, TARGET SELECTION & ADC DESIGN
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION III: LINKER, PAYLOAD & CONJUGATION INNOVATION
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION IV: ANALYTICAL DEVELOPMENT, CHARACTERISATION & CMC
- 17:00
End of Day 1 — Connexius ADC Development & Manufacturing Asia 2028, Networking Reception
Day 2 — Thursday 25 May 2028
- 09:10
SESSION V: ADC PROCESS DEVELOPMENT, SCALE-UP & TECHNOLOGY TRANSFER
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION VI: HPAPI, CONTAINMENT & SAFE ADC MANUFACTURING
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION VII: DOWNSTREAM, FORMULATION & DRUG PRODUCT MANUFACTURING
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION VIII: MANUFACTURING EXCELLENCE & ADC COMMERCIALISATION
- 17:00
End of Conference
Who Attends
By Company Profile
- Biopharma / Big Pharma / ADC Developers55%
- CDMO & CRO15%
- Technology & Service Providers20%
- Research Institutes, Academia, Government & Associations10%
By Job Function
- ADC / Oncology R&D / Antibody Engineering20%
- Linker, Payload & Conjugation15%
- Process Development / MSAT / Tech Transfer15%
- Analytical Development / CMC15%
- Manufacturing / Engineering15%
- Quality / Regulatory8%
- Business Development / Licensing / Partnerships7%
- Supply Chain / Procurement / Other5%
By Country / Market
- South Korea45%
- Japan13%
- China, Hong Kong & Taiwan15%
- Singapore & Southeast Asia12%
- Australia & New Zealand5%
- India, US, Europe & other international10%
Want to Sponsor This Event?
Explore sponsorship opportunities and discover how your brand can connect with key decision-makers across the industry.
Speak with our Sponsorship Team
Register
Contact us for group bookings of three or more delegates.
| Delegate Category | Super Early Bird Rate Valid until 31st January 2028 | Early Bird Rate Valid until 31st March 2028 | Standard Rate |
|---|---|---|---|
| Biopharma, Big Pharma, Academics, Research Institutes & Government | SGD 699 | SGD 899 | SGD 1,099 |
| Service & Solution Provider | SGD 2,049 | SGD 2,249 | SGD 2,449 |
INSIGHTS
Read before you go
- BiopharmaMarket insight
Why Singapore Is Emerging as Biopharma’s China+1 Hub
Singapore’s biopharmaceutical sector is navigating short-term production volatility while strengthening its long-term position as a trusted bridge between China and Western markets. This article examines how Singapore’s regulatory credibility, advanced manufacturing ecosystem and geopolitical neutrality support its emerging role as a China+1 hub for global biopharma.
Read more: Why Singapore Is Emerging as Biopharma’s China+1 Hub - BiopharmaMarket insight
Asia’s Biopharma Manufacturing Landscape Is Changing. Where Are the New Hubs Emerging?
Asia’s biopharmaceutical manufacturing landscape is evolving into a network of specialised ecosystems rather than a single regional hub. This article examines how South Korea, Singapore, China, India, Japan and emerging Southeast Asian markets are developing distinct roles across biologics, advanced therapies and vaccine production.
Read more: Asia’s Biopharma Manufacturing Landscape Is Changing. Where Are the New Hubs Emerging? - BiopharmaIndustry article
Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia
On 12 November 2026, Eppendorf SE broke ground on a new production facility at Bandar Cassia Technology Park in Penang. The EUR 40 million investment is the company's first manufacturing operation in Southeast Asia and will produce selected products from its Centrifuges & Instruments portfolio for laboratories worldwide, with production starting gradually in 2028.
Read more: Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia


